

RESPONSE UNDER 37 CFR 1.116  
EXPEDITED PROCEDURE  
EXAMINING GROUP 1648

PATENT

Attorney Docket No. 175912



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Boyd

Application No. 09/427,873

Filed: October 27, 1999

For: METHOD OF USING  
CYANOVIRINS TO INHIBIT  
VIRAL INFECTION

Art Unit: 1648

Examiner: J. Parkin

RECEIVED  
FEB 05 2002  
TECH CENTER 1600/2900

AMENDMENTS TO CLAIMS AFTER  
OFFICE ACTION DATED NOVEMBER 6, 2001

*Amendments to existing claims:*

20. (Amended) A method of inhibiting therapeutically or prophylactically a viral infection of a host, which method comprises administering to the host an antiviral effective amount of an isolated and purified antiviral agent selected from the group consisting of an antiviral protein, an antiviral peptide, an antiviral protein conjugate, and an antiviral peptide conjugate, wherein said antiviral protein or antiviral peptide [is encoded by an isolated and purified nucleic acid molecule encoding at least nine contiguous amino acids of] has an amino acid sequence of SEQ ID NO: 2 (or a mutant thereof) [wherein said at least nine contiguous amino acids of SEQ ID NO: 2 has antiviral activity,] whereupon administration of said antiviral effective amount of said antiviral agent, said viral infection of said host is inhibited.

22. (Amended) The method of claim 20, wherein said antiviral protein conjugate or said antiviral peptide conjugate comprises (i) [at least nine contiguous amino acids] an amino acid sequence of SEQ ID NO: 2 or a mutant thereof, [wherein said at least nine contiguous

In re Appln. of Boyd  
Application No. 09/427,873

amino acids of SEQ ID NO: 2 has antiviral activity,] and (ii) an isolated and purified viral envelope glycoprotein.